INTERNATIONAL MYELOMA SOCIETY

23rd International Myeloma Society Annual Meeting

 

23-26 September Glasgow
Close
N. Poster
Poster title
Applicant name
Status
  1-PA A Collagen-Hydroxyapatite 3D Bone Marrow Model Recapitulates Microenvironment-Mediated Drug Resistance in Multiple Myeloma Sarah Tassinari Received Received
  1-NSP An Implementation Science Approach to Bispecific Antibody Education and Care Delivery for Multiple Myeloma in Rural and Frontier Oncology Mary Steinbach Received Received
  2-NSP Building Specialty Capacity in Rural Health: Development and Outcomes of a Multiple Myeloma Project ECHO Program for Community Oncology Providers Grace Reins Received Received
  3-PA A Model for Outpatient Cilta-cel Administration and Cytokine Release Syndrome (CRS) Management without a 24-hour Clinic: Clinical Protocol and Early Results Christopher Ferreri Received Received
  3-NSP Characteristics of Multiple Myeloma Patients with Central Nervous System Involvement Daniel Zaldumbide Received Received
  4-PA A Modular AI Framework Generates Interpretable, Multi-modal Analysis Pipelines to Support Translational Research for Multiple Myeloma Ken Shain Received Received
  4-LBA Comparison between daratumumab- and isatuximab-based therapies in newly diagnosed multiple myeloma: A systematic review and meta-analysis Heinz Ludwig Received Received
  4-NSP Chronic Illness Trajectory of Patients with Multiple Myeloma Derived from Health-Related Quality of Life Data: An Integrative Review Matthias Hellberg-Naegele Received Received
  6-LBA Functional recovery with first-line daratumumab-based therapy in multiple myeloma: a multicentre observational study Juliana Holasova Received Received
  7-NSP Delivering a patient centered myeloma autograft service Lindsay Hankey Received Received
  8-PA A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma Daniel Zaldumbide Received Received
  9-PA A Pilot Study of Romosozumab in Postmenopausal Women with Myeloma-related Bone Disease and Osteoporosis Carlyn Tan Received Received
  9-NSP Examining the Role of Nurses in Multiple Myeloma (MM) Care: Insights from a European Survey Kelly Wyatt Received Received
  11-NSP From ´frailty´ to ´treatment compatibility´: a patient-driven rethinking of risk assessment in multiple myeloma Jenna Tate Received Received
  12-PA A Protocolised Multidisciplinary Workflow for Early Myeloma Directed Therapy in Suspected Light Chain Cast Nephropathy: Outcomes from a Multi-Hospital Network Xinjie Jonathan Tang Received Received
  14-PA A scoring model based on 3D telomere profiling of circulating tumor cells in the peripheral blood predicts relapse in newly diagnosed multiple myeloma patients Yulia Shifrin Received Received
  14-NSP Hyperbaric Oxygen Therapy as Adjunctive Treatment for Steroid-Refractory IEC-Colitis After BCMA CAR T: A Two-Case Experience Meghan Vigil Received Received
  15-NSP Impact of premedication de-escalation on the incidence of infusion-related reactions with isatuximab Tyler Sandahl Received Received
  15-LBA Myeloma Bone Disease: What Does a Deteriorating Osteocyte Lacuno-Canalicular Network Mean for Bone Recovery? Rebecca Andrews Received Received
  16-PA Accurate Assessment of Treatment Response in AL Amyloidosis Using Mass Spectrometry Katie Horton Received Received
  17-LBA Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Primary Analysis of the Phase 2 "STEM" (Sequential T Cell-Engagement for Myeloma) Trial Adam Cohen Received Received
  18-NSP Insights from a nurse-led care programme: A qualitative audit in a resource-constrained oncology setting Lorraine Govender Received Received
  19-NSP Maintaining Continuity of Multiple Myeloma Care During a Major Nursing Labor Disruption Through Multidisciplinary Workforce Redeployment Donna Catamero Received Received
  19-PA AI Doctor-in-the-Loop Abstraction: Enhancing Completeness in Flow Cytometry Data Abstraction for Multiple Myeloma Genomic and Immune Profiling Martha Paola Anchondo Commesse Received Received
  20-NSP Making Sense of Dollars Available for Cancer Patients With History of Toxic Environmental Exposure Samuel Shewan Received Received
  21-NSP M-FIT: An EHR-Integrated Myeloma Frailty Assessment Tool for Real Time Clinical Decision Support Kim Navarrete Received Received
  22-PA Alternative Promoter–Driven Protein Structural Programs in NDMM: Distinguishing Poor and Non-Poor Responders Garrett Larson Received Received
  22-NSP Nurse Led Care in AL Amyloidosis: Impact of a Nurse Led Clinic on Enhancing Patient Experience, Improving Outcomes and Service Evaluation. Sarah Worthington Received Received
  23-LBA From Clinical Observation to Precision Medicine: Six Decades of Research Evolution in Primary Plasma Cell Leukemia Serkan Güven Received Received
  23-PA ALTITUDE - ALTernating Induction Therapies to achieve Undetectable Disease Endpoints: Ph 1/2 Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-Risk Newly Diagnosed Multiple Myeloma Neha Korde Received Received
  24-LBA Patient understanding of Multiple Myeloma: findings of an online survey of patient perspectives on communication, information and support Rachel Hunter Received Received
  24-NSP Optimising patient experience in CAR T therapy for Multiple Myeloma: Insights into patient motivations and barriers Emma Dowling Received Received
  25-NSP Patient reported outcomes and toxicities with quadruplet regimen Isa-VRd in transplant ineligible newly diagnosed multiple myeloma: a single centre study Alex Greenwood Received Received
  25-PA An Engineered Lysosomal Protease Inhibitor Improves CAR-T Cell Therapy in Multiple Myeloma by Preventing CAR Downmodulation and Inducing the Formation of Memory CAR-T Cells Fenghuang Zhan Received Received
  27-PA An Omics-Guided Cytokine Culture Platform Sustains Primary Multiple Myeloma Cells Ex Vivo and Enables Functional Manipulation Ariene Cabantog Received Received
  29-NSP Review of Nurse and Pharmacist Survey Evidence on an On-Body Injector and Implications for Isatuximab Subcutaneous via the On-Body Injector in Patients With Multiple Myeloma Shanen Collins Received Received
  30-PA Analysis of Cell Free DNA in Monoclonal Gammopathy of Renal Significance Reveals Rare Somatic Variants and Candidate Driver Mutations Louis Williams Received Received
  31-NSP Symptom burden, unmet information needs, and the role of a patient-led support group in POEMS syndrome: a mixed-methods survey of 21 patients Alyse Anne Hart Received Received
  31-PA Analysis of subsequent BCMA-directed T-cell–redirecting therapies after treatment with belantamab mafodotin in DREAMM-7 and DREAMM-8 Darby Clifford Received Received
  32-PA Anti CD38 re-treatment is effective after an adequate wash-out period. Updated data on the DART4MM phase 2 trial on relapsed patients. Alessandro Gozzetti Received Received
  33-NSP Tocilizumab for Prevention of Cytokine Release Syndrome Associated with Ciltacabtagene autoleucel Sara Scott Received Received
  33-LBA Fixed-duration Zanubrutinib, Bendamustine, and Rituximab in symptomatic, treatment-naive Waldenström Macroglobulinemia: First Report of the Multicenter Phase 2 ZeBRa trial (WM-NET2). Andrew Branagan Received Received
  34-NSP Using a Needs-Based Assessment to Develop a Multimodal Toolkit Supporting Care Partners of Myeloma Patients Samantha Shenoy Received Received
  35-PA APOBEC3B Promotes Mitochondrial and Inflammatory Adaptation Underlying Proteasome Inhibitor Resistance in Multiple Myeloma Faezeh Borzooee Received Received
  39-PA Association between progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma (RRMM) with 2-4 lines of treatment: a real-world perspective Taani Taufa Received Received
  41-PA Atrial fibrillation in multiple myeloma: High prevalence, incidence and impact on survival. A population-based study on 8 672 patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Karin Larsson Received Received
  42-PA Automated Identification of Extramedullary Multiple Myeloma from PET/CT Reports Using Large Language Models Yael Cohen Received Received
  43-PA Baseline CMV viremia predicts CMV reactivation during CAR-T cell and bispecific antibody therapy in multiple myeloma. María del Cisne Samaniego Silva Received Received
  44-PA Baseline Immune Fitness Defines a Transcriptional Subtype of Multiple Myeloma with Excepcional Response to Daratumumab-Based Regimens in the GEM2017FIT Trial Antonio Porlan Minarro Received Received
  49-PA Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial Darby Clifford Received Received
  50-PA Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) Demonstrated Improved Outcomes as Second-Line Therapy vs Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Patients With Multiple Myeloma Darby Clifford Received Received
  52-PA Biallelic del(1p) and TP53 mutation rates and their overlap with 2+HRCA high-risk in newly diagnosed multiple myeloma: results of an ISO-accredited NHS Genomics Laboratory Hub Sina Beer Received Received
  57-PA BOSS: Safe and Feasible Outpatient Step-Up Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma Diana Cirstea Received Received
  58-PA BP2202: An Off-the-Shelf iPSC-Derived BCMA-Targeted Cellular Therapy for Multiple Myeloma &20844;&19968;&37070; &22633;&35895; Received Received
  63-PA Carfilzomib, Iberdomide, and Dexamethasone (KID) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from a Phase 1/2 Study Noa Biran Received Received
  64-PA CAR-HEMATOTOX Beyond CAR T-Cell Therapy: Utility for stratifying Hematologic and Infectious risk in Bispecific Antibodies Pina Gabriela Gálvez Zavala Received Received
  67-PA CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy with Immune Cloaking, for Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Phase 1 Trial) Erik MacLaren Received Received
  73-PA Characterization of the IKZF1 Interactome in Multiple Myeloma and Its Modulation by CELMoDs Jing Fu Received Received
  77-PA CIBMTR real-world outcomes of frail patients treated with idecabtagene vicleucel Ashley Daset Received Received
  78-PA CIBMTR Real-World Outcomes of Older Patients Treated with Idecabtagene Vicleucel Daniel Zaldumbide Received Received
  79-PA Ciltacabtagene Autoleucel as Early versus Late Line of Therapy for Patients with Relapsed Refractory Multiple Myeloma: A Real World Analysis Aytaj Mammadzadeh Received Received
  81-PA Circulating Plasma Cells and C-Reactive Protein Improve ISS-Based Risk Stratification in Japanese Multiple Myeloma Yusuke Okayama Received Received
  85-PA Clearance kinetics of monoclonal immunoglobulin detected by mass spectrometry in multiple myeloma patients in complete response Elena Alejo Received Received
  86-PA Clinical and Biological Predictors of Durable Response to Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM) Gliceida Galarza Received Received
  88-PA Clinical and Treatment Factors Associated With Super-Response in Multiple Myeloma: Identifying Patients Most Likely to Approach the IMS Emerging Cure Criteria Magaly Valeria Escobedo Cruz Received Received
  89-PA Clinical benefit of anti-cd38 monoclonal antibodies in newly diagnosed multiple myeloma: analysis of the subgroup with renal impairment. Ana Garzo Received Received
  94-PA Clinical impact of diagnosis to treatment interval in transplant-ineligible NDMM treated with DRd: a multicenter real-world study in Japan. Kazuhito Suzuki Received Received
  95-PA Clinical implications of discordant frailty assessment in non-transplant eligible patients with newly diagnosed multiple myeloma: Results from the randomized phase IV REAL MM trial Lorenzo Cani Received Received
  96-PA Clinical Outcomes and Predictors of Survival in Central Nervous System (CNS) Multiple Myeloma: A Retrospective Cohort Study Bita Bashy Received Received
  98-PA Clinical screening for Monoclonal Gammopathy – prevalence and outcomes Sumeet Yadav Received Received
  100-PA Clinical trial evidence informing efficacy and safety of FDA-approved treatments in relapsed and refractory multiple myeloma for patients after quadruple-class exposure Ashley Daset Received Received
  104-PA Comparative Analysis of Isa SC VRd (ISASOCUT, Weekly Bortezomib) and Isa IV VRd (IMROZ, Twice-Weekly Bortezomib): 20-Month Follow-Up in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients Shanen Collins Received Received
  105-PA Comparative analysis of single-center survival rates between patients eligible for autologous hematopoietic stem cell transplantation and those who did not undergo transplantation in multiple myeloma Hailong Yuan Received Received
  106-PA Comparative Effectiveness of Quadruplet vs. Triplet Induction Regimen in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Target Trial Emulation Amandeep Godara Received Received
  115-PA Cost per Responder for Teclistamab-Daratumumab versus Daratumumab, Pomalidomide, Dexamethasone (DPd), and Daratumumab, Bortezomib, Dexamethasone (DVd) in Relapsed Refractory Multiple Myeloma Patients Emily Eagles Received Received
  116-PA Cost-Effectiveness of High-Dose Therapy with Autologous Stem Cell Transplantation Versus Non-Transplant Strategy in Newly Diagnosed Multiple Myeloma: A Real-World Institutional Analysis from India Reetu jain Received Received
  123-PA Cystatin C Unmasks Hidden Renal Impairment and Independently Predicts Mortality in Newly Diagnosed Multiple Myeloma Janeth Araujo Cardenas Received Received
  125-PA Cytomegalovirus Reactivation after BCMA CAR T-cell Therapy Among Relapsed Refractory Multiple Myeloma Patients Hamza Hamza Received Received
  127-PA Daratumumab plus bortezomib maintenance after DVMP induction in transplant-ineligible newly diagnosed multiple myeloma: 3-year real-world outcomes beyond the ALCYONE strategy Luis-Esteban Tamariz-Amador Received Received
  131-PA Dasatinib for Cranial Nerve Palsy following Cilta-Cel Peter Forsberg Received Received
  133-PA Deep Generative Modeling of Multi-Cohort Flow Cytometry Reveals a T-Cell Exhaustion Signature Predictive of Post-ASCT Outcomes in Myeloma Kevin Miller Received Received
  134-PA Deep Sustained Response to Belantamab Mafodotin Despite Reversible Grade 4 Ocular Toxicity in Relapsed/Refractory Multiple Myeloma in the Brazilian Public Health System Marina Ughini Received Received
  138-PA Description of step-up dosing and adverse events after elranatamab initiation in patients with relapsed or refractory multiple myeloma: results of the interim analysis of the real-world AMbrELA study Alina Florou Received Received
  139-PA Design of the phase 2 ALANIS study: Belantamab mafodotin in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed amyloid light chain amyloidosis Laura Leistikow Received Received
  144-PA Development of BCMA-Specific TAC-T cells: Enabling TACtful, a First-in-Human Study in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Annette Hay Received Received
  145-PA Development of BMS-986453, a dual-targeting BCMA×GPRC5D chimeric antigen receptor for the treatment of multiple myeloma Ashley Daset Received Received
  147-PA Discovering Actionable Steps: Patient Empowerment & The MMRF Patient Navigation Center Veronica Bohorquez-Medd Received Received
  151-PA Dose-Optimized Selinexor-Based Regimens in Plasmacytoma-Associated Relapsed/Refractory Multiple Myeloma: Real-World Imaging and Treatment Persistence Outcomes Dionisios Stoumbos Received Received
  152-PA Double hit ultra-high risk myeloma treated with Isa-VRDc induction and Isa-VRD consolidation: Sub analysis of the UKMRA RADAR trial in newly diagnosed transplant eligible patients Karthik Ramasamy Received Received
  153-PA DREAMM-15: a study assessing the efficacy and safety of extended-dose belantamab mafodotin in combination with standard-of-care therapies in patients with relapsed/refractory multiple myeloma Darby Clifford Received Received
  155-PA Duffy Null Genotype Modifies Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Chaitanya Acharya Received Received
  156-PA Dynamic changes in soluble BCMA (sBCMA) versus soluble Free Light Chains (FLC) for the early prediction of therapeutic response in multiple myeloma. Maria Livia Del Giudice Received Received
  166-PA Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From the Phase 2 IZALCO Study Shanen Collins Received Received
  171-PA Efficacy, Safety, and De-escalation Strategies of Teclistamab in Relapsed/Refractory Multiple Myeloma: A Real-World Cohort with 24-Month Follow-up Mariana Kerbauy Received Received
  172-PA Elevated APOBEC3B Expression Marks Functionally High-Risk Multiple Myeloma with Early Failure of Frontline PI/IMiD Therapy Afsaneh Panahi Received Received
  173-PA Elevated circPTK2 Expression Is Associated with Extramedullary Disease and Shows Diagnostic Potential in Multiple Myeloma Xiaoling Chen Received Received
  174-PA eMMpower-CART: Real-World Insights into Early-Line Cilta-cel Outcomes in Multiple Myeloma (MM) Binod Dhakal Received Received
  181-PA Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy Daniel Zaldumbide Received Received
  182-PA Ethnic and Gender Variations in Newly Diagnosed Multiple Myeloma Patients – Israeli Jewish and Arab Patients Cohorts Kareem Midlej Received Received
  183-PA Evaluating MRD-negative CR as a surrogate endpoint for PFS in CAR T–treated relapsed and refractory multiple myeloma: a meta-analysis of clinical trials Ashley Daset Received Received
  185-PA Evaluation of Patient-Reported Outcomes and Subgroup Analysis With Subcutaneous Isatuximab Delivered via On-Body Injector Compared With Intravenous Delivery From the Phase 3 IRAKLIA Trial Shanen Collins Received Received
  187-PA Evaluation of the Hevylite Test as a prognostic factor and its association with infections in patients with multiple myeloma Maricy Lopes Received Received
  188-PA Evaluation of triple-class exposed patients in a Brazilian referral center Ana Luiza Dias Received Received
  189-PA Evolution of functional status in non-transplant-eligible patients with multiple myeloma during first-line treatment Leticia Gomez Serrano Received Received
  193-PA Extrachromosomal DNA shapes aggressive transcriptional states in multiple myeloma Hyunsoo Cho Received Received
  194-PA Extramedullary Disease in Newly Diagnosed Multiple Myeloma: Real-World Evidence from a Latin American Referral Center Andy Yajaira Mejía Castro Received Received
  196-PA Extrapolated median progression-free survival with belantamab mafodotin/lenalidomide/dexamethasone exceeds7 years in intermediate-fit or frail, transplant-ineligible, newly diagnosed multiple myeloma Laura Leistikow Received Received
  198-PA Feasibility and safety of outpatient biespecific antibody administration in multiple myeloma: a single-center experience Diego Conde-Royo Received Received
  213-PA Genomic Determinants of Response to Iberdomide Combination and Monotherapy in Early Relapsed Multiple Myeloma Benjamin Diamond Received Received
  214-PA Genotype-informed single-cell RNA-seq resolves functional subclonal heterogeneity in multiple myeloma Alessia DAnna Received Received
  216-PA HDP-101, a BCMA-Targeting Antibody-Drug Conjugate with a Novel Amanitin Payload, Establishes the Recommended Phase 2 Dose (RP2D) in a clinical Phase 1 trial on Relapsed/Refractory Multiple Myeloma Lei Wang Received Received
  217-PA Health care costs in front line treatment with a CD38-antibody versus VRD - a cost-effectiveness analysis Hannah Söderholm Received Received
  219-PA Health-Related Quality of Life (HRQoL) is influenced by clinical features rather than genetic risk in newly diagnosed myeloma patients: Results from the UK Myeloma Research Alliance (MRA) RADAR trial Catherine Lecat Received Received
  222-PA Hematology-Oncologists´ Perspectives on an On-Body Injector for Administration of Large-Volume Subcutaneous Drugs: Implications for Isatuximab Subcutaneous for Multiple Myeloma Shanen Collins Received Received
  224-PA Hidden Heterogeneity in Multiple Myeloma Outcomes Among Asian American and Pacific Islander Subgroups: A SEER Analysis, 2012–2022 Abhiraj Saxena Received Received
  225-PA High MRD- Rates and Prolonged PFS with Belantamab Mafodotin Plus Daratumumab, Lenalidomide, and Dexamethasone in Transplant Ineligible Newly-Diagnosed Myeloma: Results of the Phase 1/2 BelaDRd Study Evangelos Terpos Received Received
  226-PA High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma: Updated Real-World Outcomes from India : A Single-Centre Experience of 203 Patients Reetu jain Received Received
  229-PA Home based subcutaneous therapy in elderly and frail patients with multiple myeloma: A single centre real world experience from India Reetu jain Received Received
  230-PA How to select ASCT candidates in patients with suboptimal stem cell mobilisation- a case study Kate Xu Received Received
  236-PA Immune dysregulation of non malignant B cells reveals early functional derangement across plasma cell dyscrasias Matteo Claudio Da Vià Received Received
  238-PA Immune Recovery and Infectious Events with Ixazomib versus Anti-CD38 Maintenance in MRD-Negative Transplant-Ineligible NDMM Masaki Iino Received Received
  240-PA Impact of Clinical Whole Genome Sequencing in Immunotherapy Exposed Patients Jonathan Keats Received Received
  242-PA Impact of Immunomodulatory (IMiD) Containing Holding Therapy (HT) Regimens on Outcomes in Relapsed/Refractory (RRMM) Patients Receiving Chimeric Antigen Receptor – T cell (CAR-T) Therapy Veena Krishnan Received Received
  244-PA Impact of Lecture on Knowledge of IM Residents In Diagnosing and Managing CRS and ICANS Stephen Caucci Received Received
  245-PA Impact of prior anti-BCMA antibody-drug conjugate exposure and high-risk cytogenetics on outcomes with BCMA bispecifics in relapsed/refractory multiple myeloma: a single centre real-world analysis Martin Kaiser Received Received
  246-PA Impact of prior Daratumumab or Isatuximab: an analysis of relapsed and refractory multiple myeloma (RRMM) patients treated with melflufen plus dexamethasone in the OP-106 HORIZON study Fanni Skogh Received Received
  249-PA Improving real-world outcomes in the frail and elderly with myeloma: Data from the UK Haematological Malignancy Research Network Frances Seymour Received Received
  256-PA Infection Spectrum, Etiology and Severity in Patients Treated with Teclistamab for Relapsed/Refractory Multiple Myeloma: A Real-World Cohort Mariana Kerbauy Received Received
  262-PA Integrated multi-omic profiling reveals compensatory cytotoxic CD8 T-cell rewiring, NK-cell remodeling, and systemic immune dysfunction during progression from MGUS to multiple myeloma Cirino Botta Received Received
  267-PA Intermediate Dose Of Arac As Safe And Effective Salvage Therapy For Multiple Myeloma Poor Mobilizers Paola Boggione Received Received
  268-PA Investigating and targeting lipid-induced resistance to venetoclax in multiple myeloma Remya Nair Received Received
  270-PA Isatuximab in combination (Isa VRd) in patients with newly diagnosed multiple myeloma not candidates for transplant: clinical practice experience in hospitals in Spain. María Esther Clavero Received Received
  271-PA Isatuximab Plus Pomalidomide-Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Subgroup Analysis by Prior Anti-CD38 Exposure From the Phase 3 IRAKLIA Trial Shanen Collins Received Received
  272-PA Ixazomib, lenalidomide, dexamethasone treatment with cytogenetic risk-based maintenance in transplant-eligible multiple myeloma patients: The expanded results of a phase 2 study Raija Silvennoinen Received Received
  273-PA Kinase-Independent PIM2-MYC Signaling Controls MYC-Driven Transcriptional Programs in Multiple Myeloma Christopher Schorr Received Received
  274-PA Kinetics of Multi-modality Minimal Residual Disease (MRD) Testing During Isatuximab and Lenalidomide (IsaR) Maintenance Ravi Kishore Narra Received Received
  279-PA Lesion-level PET/CT analysis identifies anatomic and biologic predictors of progression after BCMA CAR T-cell therapy in relapsed / refractory multiple myeloma Alexandra Dreyfuss Received Received
  281-PA Lipid droplets in multiple myeloma: association with disease progression and therapeutic resistance Mónica González Received Received
  286-PA Longitudinal Single-Cell Profiling Reveals Reproducible Clonal Expansion of Cytotoxic CD8? TEMRA Cells Following Daratumumab-Based Therapy Chaitanya Acharya Received Received
  288-PA Long-Term (≥5-Year) Remission and Survival With Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma With 1-3 Prior Lines of Therapy: CARTITUDE-2 Cohort A Ellen Walsh Received Received
  290-PA Low CRS and ICANS rates during step up dose reinitiation after prolonged dose delay of bispecific antibodies in multiple myeloma Catherine Lecat Received Received
  291-PA Lysosome-mediated selective removal of eccDNA drives proteasome inhibitor resistance of multiple myeloma by ubiquitination and Piezo1-dependent ESCRT Huihan Wang Received Received
  292-PA Macrophage Reprogramming, Not CD8 T Cell Dynamics, Characterizes Durable Disease Control Following PD-1 Blockade in Smoldering Myeloma Kane Foster Received Received
  295-PA Mass Spectrometry Identifies Actionable Myeloma Relapse Eight Months Before Electrophoretic Detection Katie Horton Received Received
  296-PA Matching-adjusted indirect comparison of belantamab mafodotin, bortezomib, dexamethasone vs carfilzomib, lenalidomide, dexamethasone in relapsed/refractory multiple myeloma Laura Leistikow Received Received
  297-PA Matching-Adjusted Indirect Comparisons (MAICs) of Anitocabtagene Autoleucel (anito-cel) versus Teclistamab and Talquetamab for the Treatment of 4L+ Relapsed and/or Refractory Multiple Myeloma (RRMM) Krina Patel Received Received
  298-PA Matching-adjusted indirect comparisons (MAICs) of efficacy and safety outcomes for anitocabtagene autoleucel versus ciltacabtagene autoleucel in 4L+ relapsed and/or refractory multiple myeloma (RRMM) Surbhi Sidana Received Received
  302-PA Measuring What Matters: Patient Behavioral Outcomes Across MMRF Education Programs Veronica Bohorquez-Medd Received Received
  304-PA Mezigdomide (CC-92480) following idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma is safe and leads to deepening of responses MURALI JANAKIRAM Received Received
  306-PA MGUS with advanced chronic kidney disease: clinical profile, FLC ratio interpretation, and progression to multiple myeloma in a tertiary hematology center DALILA CYSNE Received Received
  307-PA Monoclonal Gammopathy of Renal Significance: Experience at a Single Center and Implementation of a Multidisciplinary Committee Pilar Lancho Lavilla Received Received
  309-PA Moving ahead on the interpretation of t(14;16) driver alteration role in the era of novel agent therapy in Multiple Myeloma. Luca Vavolo Received Received
  311-PA Multicentric Evaluation of SPIRIT IT : Artificial Intelligence to detect and characterize M-protein Nathalie SASSINE Received Received
  312-PA Multi-Modal Single-Cell Profiling of MRD-Negative Patients Identifies Early Immune Signatures Predicting Prolonged Response or Relapse in Multiple Myeloma Alessandro Lagana Received Received
  313-PA Multi-omics profiling unveils exclusive molecular signature of multiple myeloma cells harbouring differential TP53 genetic perturbations Phaik Ju Teoh Received Received
  315-PA MY.13: A Canadian-Led Non-inferiority Phase III Trial in Progress Integrating Equity Principles in Transplant-Ineligible (TIE) Newly-Diagnosed (ND) Multiple Myeloma (MM) María Comelles Received Received
  316-PA Neoantigen viral vector vaccination provides effective and durable tumor control in an aggressive Multiple Myeloma model Marta Chesi Received Received
  319-PA Next generation flow (NGF) identifies peculiar aberrant subtypes of clonal plasma cells in newly diagnosed multiple myeloma patients. A single center experience on 293 patients. Alessandro Gozzetti Received Received
  320-PA NSD2 induces global chromatin changes to potentiate IL-6 signaling in multiple myeloma Robert Chavez Received Received
  322-PA Open-label, single-arm phase Ib/II study of immune combination therapy with belantamab mafodotin and elotuzumab in patients with relapsed/refractory multiple myeloma (RRMM) Natalia Neparidze Received Received
  324-PA Optimized computationally engineered CD70-targeting virus-free CRISPR knock-in CAR T cells for high-risk multiple myeloma Bonell Patino-Escobar Received Received
  325-PA Optimizing Risk Stratification in Newly Diagnosed Multiple Myeloma, the role of NGS on the New Consensus Genomic Staging: A multicenter descriptive study. Marina González Martínez Received Received
  327-PA Outcomes of multiple myeloma patients with del17p with coexistent trisomy/tetrasomy 17 Richa Parikh Received Received
  328-PA Outcomes of Multiple Myeloma with an Isolated Bone Lesion and Limited Marrow Involvement Treated with Localized Radiotherapy Alone Daniel Packard Received Received
  329-PA Outcomes of Outpatient Step Up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal) in Relapsed/Refractory Multiple Myeloma (RRMM): Findings from Academic and Community Practices in the USA Emily Eagles Received Received
  330-PA Outcomes Of Patients Treated With Isatuximab Based Regimens For Relapsed Refractory Multiple Myeloma From British Columbia Jonathan Isenberg Received Received
  331-PA Outcomes of Triple-Class Exposed Relapse/Refractory Multiple Myeloma Patients Treated with Carfilzomib-Based Regimens: Real-World, Single Center Study Tamir Shragai Received Received
  332-PA Outpatient Administration of Bispecific Antibody Therapy for Multiple Myeloma in Community Oncology Practice Christopher Strouse Received Received
  334-PA Outpatient Step-Up Dosing of Teclistamab or Talquetamab with Prophylactic Tocilizumab in Patients with Relapsed/Refractory Multiple Myeloma: Real-World Evidence from a Large US Cancer Center Emily Eagles Received Received
  335-PA Overall survival in multiple myeloma is improving but rates of attrition remain unchanged Christopher Parrish Received Received
  337-PA Patient Experience, Satisfaction and Preference with Isatuximab Subcutaneous On-Body Injector from the Phase 3 IRAKLIA and Phase 2 IZALCO Clinical Trials Shanen Collins Received Received
  340-PA POLB 001, an oral p38 MAPK inhibitor for the prevention of cytokine release syndrome Liam Tremble Received Received
  341-PA Patient-Reported Quality of Life and Real-World Outcomes with Use of Daratumumab Regimens in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Multicenter Study Sabrina Browning Received Received
  343-PA PFS2 outcomes in DREAMM-8: belantamab mafodotin (belamaf)-pomalidomide-dexamethasone (BPd) vs pomalidomide-bortezomib-dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM) Emily Felton Received Received
  346-PA Phase 1/2, open-label, platform study of surzetoclax with etentamig in biomarker-selected patients with relapsed/refractory multiple myeloma (RRMM) Daniel Zaldumbide Received Received
  349-PA Phase 3 Randomised Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light Chain Amyloidosis Ashutosh Wechalekar Received Received
  351-PA Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone (D-ClaPd) in Multiple Myeloma Patients Previously Exposed to Daratumumab Joshua Kassner Received Received
  358-PA Post-Infusion Immunophenotypic And Functional Characteristics Of Arlocabtagene Autoleucel (Arlo-Cel) In A First-In-Human (FiH), Phase 1 Trial In Relapsed/Refractory Multiple Myeloma (RRMM) Daniel Zaldumbide Received Received
  359-PA Preclinical evaluation of ß-glucuronide linker-based BCMA ADCs with MMAF, proPBD, and TOP1 inhibitor payloads support differentiated clinical development strategies Matthew Sender Received Received
  361-PA Preemptive Tocilizumab in Patients with Relapsed-Refractory Multiple Myeloma Receiving Bispecific: A Case Series Rebecca Tokarski Received Received
  365-PA Prognostic Impact of [18F] FDG PET/CT Before and After BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Analysis Luis Esteban Tamariz Amador Received Received
  366-PA Prognostic impact of CDKN2C mutations in Newly Diagnosed Multiple Myeloma Patients Anaïs Schavgoulidze Received Received
  368-PA PROGNOSTIC INDECES IN MULTIPLE MYELOMA: MERGING BIOLOGICAL AND CLINICAL RISK FACTORS – ON THE BRINK OF THE NEW PROGNOSTIC MODEL Jelena Bila Received Received
  373-PA Prospective study of Peripheral Residual Disease (PRD) Monitoring by Clonotypic Mass Spectrometry (EasyM) in patients with Newly Diagnosed Multiple Myeloma (NDMM) Rintu Sharma Received Received
  375-PA Proteogenomic Integration Reveals Predictive Signatures of Ibrutinib Response in Waldenström Macroglobulinemia Christos Vlachos Received Received
  377-PA Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients with Primary Plasma Cell Leukemia (QUANTUM): A Prospective Randomized Phase 2 Study Daniel Zaldumbide Received Received
  380-PA Radiographic response to bridging therapy is predictive of efficacy post BCMA CAR T-cell therapy in relapsed / refractory multiple myeloma Alexandra Dreyfuss Received Received
  384-PA Real Life Data of Belantamab Mafodotin for Patients with Early Relapsed Multiple Myeloma Tamir Shragai Received Received
  385-PA Real-time single-cell profiling to guide T-cell redirecting treatment sequence in multiple myeloma Eric Letouzé Received Received
  386-PA Real-world (RW) characteristics, treatment patterns, and outcomes in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in Europe: Results from the HARMONY Big Data Platform Beth Stapleton Received Received
  387-PA Real-world (RW) infection-related healthcare resource utilization (HCRU) and costs in patients (pts) with multiple myeloma (MM) receiving T-cell redirecting therapies (TCRTs) Daniel Zaldumbide Received Received
  388-PA Real-world burden of infections in patients with relapsed or refractory multiple myeloma treated with elranatamab in Japan: Findings from the SUMMIT study Alina Florou Received Received
  389-PA Real-World Dexamethasone Dose Intensity Patterns in Induction Therapy for Newly Diagnosed Multiple Myeloma in a Mexican Cohort Diego Garzón Recalde Received Received
  390-PA Real-World effectiveness of elranatamab in patients with relapsed or refractory multiple myeloma in Japan: Results from the SUMMIT study Alina Florou Received Received
  395-PA Real-World Evaluation of Prophylactic Anakinra for Toxicity Mitigation in BCMA CAR-T Therapy Rishi Nair Received Received
  397-PA Real-world experience with early-line ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Brandon Kale Received Received
  398-PA Real-World Experience with Teclistamab and Talquetamab Combination Therapy in Relapsed/Refractory Multiple Myeloma Andrew Kowalski Received Received
  400-PA Real-World Outcomes and Predictors of Bispecific Antibody Therapy Response in a Racially Diverse Multiple Myeloma Cohort Joshua Kassner Received Received
  401-PA Real-World Outcomes following Second Line Treatment for Multiple Myeloma in Wales Izabelle Wood Received Received
  403-PA Real-World Outcomes of Anti-CD38-Based Quadruplet Induction Regimens in Newly Diagnosed Multiple Myeloma: A Multinational Latin American Experience. patricio duarte Received Received
  407-PA Real-world patient characteristics, general safety profile, and treatment patterns of elranatamab (ELRA) use in relapsed refractory multiple myeloma (RRMM): interim results of the AMbrELA study Alina Florou Received Received
  408-PA Real-World Progression-Free Survival Among Non-Transplanted Newly Diagnosed Multiple Myeloma Patients Initiating Frontline DVRd vs VRd Philippe Thompson-Leduc Received Received
  409-PA Real-World Survival Outcomes and Treatment Patterns Among Frail Older Adults with Multiple Myeloma: A United States Veterans Affairs Cohort Study from 2000 to 2023 Armand Ghazanfar Received Received
  412-PA Recurrent Anterior Uveitis Associated With Teclistamab in Relapsed/Refractory Multiple Myeloma Iryna Luts Khoroz Received Received
  414-PA Repurposing Polyether Ionophores to Target Stem-like Compartments and Microenvironmental Resistance in Multiple Myeloma Dana Cholujova Received Received
  416-PA Resolution of Clonal Cytopenia of Undetermined Significance Following Autologous Stem Cell Boost in a Patient with Multiple Myeloma: A Case Report Rebecca Tokarski Received Received
  417-PA Response to Bispecifics in Relapsed-Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series Rebecca Tokarski Received Received
  422-PA Revisiting Biclonal Gammopathies in the Era of High-Resolution Mass Spectrometry with EXENT® Isabelle Sliepen Received Received
  424-PA Risk-directed front-line therapy for Newly Diagnosed Multiple Myeloma (NDMM) incorporating selinexor - The RIDDLE-MX trial AMaRC 21-04. Sueh-li Lim Received Received
  427-PA Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Myung-won Lee Received Received
  428-PA Role of BCMA modulation in the effect of Belantamab mafodotin in Multiple Myeloma Amaya Llorente Received Received
  430-PA Safety and Efficacy of Talquetamab in Multiple Myeloma Patients with Renal Insufficiency Karen Johns Received Received
  432-PA Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials Shanen Collins Received Received
  433-PA Safety Profile and Impact of Body Weight on Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Yuko Shirouchi Received Received
  434-PA Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach Damian Mikulski Received Received
  437-PA Selinexor, mezigdomide, and dexamethasone in relapsed/refractory multiple myeloma (RRMM) patients (pts) relapsing / ineligible for T-cell–redirecting therapy (TCRT): STOMP Phase 1 preliminary results Nancy Chidel Received Received
  444-PA Single Cell RNA-Seq-Based 5-Axis Transcriptomic Phenotyping Integrated with Cytogenetic Risk Scores in Multiple Myeloma: Chr1q Gain Is the Dominant Independent Predictor of Overall Survival Byung Woo Yoon Received Received
  446-PA Single sample prediction of multiple myeloma high-risk genomic events using bulk and single-cell gene expression Steven Foltz Received Received
  450-PA Single-Cell Phylogenetic Dynamics during Immunotherapy and at Minimal Residual Disease Timepoints in Multiple Myeloma Rosa Toenges Received Received
  455-PA Skeletal-Related Events and Treatment-Associated Toxicities with Bone-Directed Therapy Use in Transplant Eligible Newly Diagnosed Multiple Myeloma sidharth mahajan Received Received
  458-PA Spatial Transcriptomics and Proteomics determinants of Resistance to T Cell Engagers in Extramedullary Multiple Myeloma Seunghee Kim-Schulze Received Received
  459-PA Spatially Resolved Transcriptomics Delineates "Immunocores" and Clonal Resistance Architecture in Extramedullary Multiple Myeloma Alessandro Lagana Received Received
  460-PA Spatio-Temporal Architecture of the Bone Marrow Niche in Relapsed/Refractory Multiple Myeloma upon T-cell-engagers therapies Francesca Lazzaroni Received Received
  461-PA Stage- and Subset-Specific Immune Checkpoint Remodeling in the Bone Marrow Microenvironment of Multiple Myeloma Compared Across B-Cell Malignancies Dana Cholujova Received Received
  463-PA Stem cell mobilization after two cycles in the anti-CD38 era: Does earlier timing improve apheresis outcomes? Álvaro García García Received Received
  465-PA Stem-like CD8+ memory effector T cells are prognostic and predictive of response in transplant-eligible newly diagnosed patients receiving VRd and autologous stem cell transplant Chaitanya Acharya Received Received
  466-PA Survival Outcomes Associated with Daratumumab Use in Multiple Myeloma: A Retrospective Real-World Cohort Analysis Diego Cruz-Contreras Received Received
  467-PA Survival Trends in Patients with Newly-Diagnosed Multiple Myeloma: A Retrospective, 10-Year, Population-Based Analysis (2010-2019) Jesse Shustik Received Received
  468-PA Surzetoclax: A Potentially Best-in-class BCL-2 inhibitor for the treatment of Multiple Myeloma with t(11;14) translocation or high BCL-2 expression Cory Alvey Received Received
  473-PA T- and NK-cell Immunomodulatory reprogramming by cemsidomide, a novel and potent MonoDAC® degrader, in relapsed/refractory Multiple Myeloma: Biomarker results from CFT7455-1101 Arm B2 cohort. Riadh Lobbardi Received Received
  474-PA T cell engager therapy impairs antiviral immunity through depletion of viral-reactive CX3CR1+ CD8+ T cells in multiple myeloma Mansour Poorebrahim Received Received
  482-PA Targeting p300/CBP to overcome IMiD resistance Hannah Barge Received Received
  483-PA TARGET-LATAM Targeted Bispecific Antibodies Against BCMA and GPRC5D in Relapsed/Refractory Multiple Myeloma A Real-World Comparative Analysis from the GELAMM Group Aline Guillermina Ramírez Alvarado Received Received
  487-PA The Changing Landscape of Thrombosis in Multiple Myeloma: Temporal Trends from a Real-World Longitudinal Cohort Aline Guillermina Ramírez Alvarado Received Received
  492-PA The Role of Prehabilitation in Individuals Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma Shannon Strader Received Received
  495-PA Three-Dimensional Single-Cell Telomere Profiling Reveals Distinct Multiple Myeloma and AL Amyloidosis Clones in Overlapping Plasma Cell Disorders Yulia Shifrin Received Received
  507-PA Treatment Patterns and Outcomes in Primary Plasma Cell Leukemia: A Single-Center Case Series Terri Parker Received Received
  508-PA Trends and Disparities in Infection Associated Mortality Among Older Adults with Multiple Myeloma: A CDC WONDER Analysis from 1999 to 2023 Ahad Moulvi Received Received
  510-PA Trial in progress: phase 1 trial of arlocabtagene autoleucel plus mezigdomide or elranatamab in patients with relapsed/refractory multiple myeloma Ashley Daset Received Received
  513-PA Underrepresentation in Randomized Clinical Trials Identifies a High-Risk Real-World Population in Newly Diagnosed Multiple Myeloma Joao Tadeu Souto Filho Received Received
  514-PA Unequal transition towards survivorship in multiple myeloma across Europe, 2000–2022: a population-level analysis Max Mendez Received Received
  515-PA Updated exploratory multivariable analyses of differential impact of Duffy genotype on PFS with lenalidomide-bortezomib-dexamethasone (RVd) alone or RVd+ASCT in newly diagnosed multiple myeloma (NDMM) Steve Hill Received Received
  518-PA Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Patients With Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study Shanen Collins Received Received
  522-PA Utility of Local Cytogenetic Testing for Risk-Stratified Therapy in Newly Diagnosed Multiple Myeloma: UKMRA RADAR Experience Matthew Jenner Received Received
  526-PA Waldenström Macroglobulinemia in a Resource-Constrained Setting: Clinical Characteristics, Treatment Patterns and Survival Outcomes from a 15-Year Cohort Sharon Lionel Received Received
  527-PA Whole genome sequencing of circulating multiple myeloma cells with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance Francois Aguet Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
04:40
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

23rd International Myeloma Society Annual Meeting

 

23-26 September Glasgow
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 23/09/2030 TO 23/09/2030
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
Logo Cert